These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 23807360)
61. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141 [TBL] [Abstract][Full Text] [Related]
62. The effect of increased inoculum on oral rotavirus vaccine take among infants in Dhaka, Bangladesh: A double-blind, parallel group, randomized, controlled trial. Lee B; Dickson DM; Alam M; Afreen S; Kader A; Afrin F; Ferdousi T; Damon CF; Gullickson SK; McNeal MM; Bak DM; Tolba M; Carmolli MP; Taniuchi M; Haque R; Kirkpatrick BD Vaccine; 2020 Jan; 38(1):90-99. PubMed ID: 31607603 [TBL] [Abstract][Full Text] [Related]
63. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults. Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919 [TBL] [Abstract][Full Text] [Related]
64. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial. Isanaka S; Langendorf C; McNeal MM; Meyer N; Plikaytis B; Garba S; Sayinzoga-Makombe N; Soumana I; Guindo O; Makarimi R; Scherrer MF; Adehossi E; Ciglenecki I; Grais RF PLoS Med; 2021 Jul; 18(7):e1003655. PubMed ID: 34214095 [TBL] [Abstract][Full Text] [Related]
65. A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Dennehy PH; Vaccine; 2006 May; 24(18):3780-1. PubMed ID: 16111790 [TBL] [Abstract][Full Text] [Related]
66. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Clements-Mann ML; Dudas R; Hoshino Y; Nehring P; Sperber E; Wagner M; Stephens I; Karron R; Deforest A; Kapikian AZ Vaccine; 2001 Sep; 19(32):4676-84. PubMed ID: 11535316 [TBL] [Abstract][Full Text] [Related]
67. Prevaccination Rotavirus Serum IgG and IgA Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants. Moon SS; Groome MJ; Velasquez DE; Parashar UD; Jones S; Koen A; van Niekerk N; Jiang B; Madhi SA Clin Infect Dis; 2016 Jan; 62(2):157-65. PubMed ID: 26400993 [TBL] [Abstract][Full Text] [Related]
68. Rotavirus strain surveillance for three years following the introduction of rotavirus vaccine into Belém, Brazil. Guerra SF; Linhares AC; Mascarenhas JD; Oliveira A; Justino MC; Soares LS; Müller EC; Brasil P; Tuboi S; Ortega-Barria E; Colindres R J Med Virol; 2015 Aug; 87(8):1303-10. PubMed ID: 25879653 [TBL] [Abstract][Full Text] [Related]
69. Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine. Cowley D; Boniface K; Bogdanovic-Sakran N; Kirkwood CD; Bines JE Hum Vaccin Immunother; 2017 Aug; 13(8):1908-1915. PubMed ID: 28481726 [TBL] [Abstract][Full Text] [Related]
70. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants. Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027 [TBL] [Abstract][Full Text] [Related]
71. Impact of rotavirus vaccination in Australian children below 5 years of age: a database study. Pendleton A; Galic M; Clarke C; Ng SP; Ledesma E; Ramakrishnan G; Liu Y Hum Vaccin Immunother; 2013 Aug; 9(8):1617-25. PubMed ID: 23733041 [TBL] [Abstract][Full Text] [Related]
72. Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Xia S; Du J; Su J; Liu Y; Huang L; Yu Q; Xie Z; Gao J; Xu B; Gao X; Guo T; Liu Y; Zhou X; Yang H Vaccine; 2020 Oct; 38(46):7393-7400. PubMed ID: 32451212 [TBL] [Abstract][Full Text] [Related]
73. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Rojas OL; Caicedo L; Guzmán C; Rodríguez LS; Castañeda J; Uribe L; Andrade Y; Pinzón R; Narváez CF; Lozano JM; De Vos B; Franco MA; Angel J Viral Immunol; 2007; 20(2):300-11. PubMed ID: 17603846 [TBL] [Abstract][Full Text] [Related]
74. The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis plan. Jones MA; Graves T; Middleton B; Totterdell J; Snelling TL; Marsh JA Trials; 2020 Aug; 21(1):741. PubMed ID: 32843086 [TBL] [Abstract][Full Text] [Related]
75. A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Rathi N; Desai S; Kawade A; Venkatramanan P; Kundu R; Lalwani SK; Dubey AP; Venkateswara Rao J; Narayanappa D; Ghildiyal R; Gogtay N; Venugopal P; Palkar S; Munshi R; Kang G; Babji S; Bavdekar A; Juvekar S; Ganguly N; Niyogi P; Ghosh Uttam K; Rajani HS; Kondekar A; Kumbhar D; Mohanlal S; Agarwal MC; Shetty P; Antony K; Gunale B; Dharmadhikari A; Tang Y; Kulkarni PS; Flores J Vaccine; 2018 Dec; 36(52):7943-7949. PubMed ID: 30420116 [TBL] [Abstract][Full Text] [Related]
76. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants. Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377 [TBL] [Abstract][Full Text] [Related]
77. Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand. Chen MY; Kirkwood CD; Bines J; Cowley D; Pavlic D; Lee KJ; Orsini F; Watts E; Barnes G; Danchin M Hum Vaccin Immunother; 2017 May; 13(5):1126-1135. PubMed ID: 28059609 [TBL] [Abstract][Full Text] [Related]
78. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Dhingra MS; Kundu R; Gupta M; Kanungo S; Ganguly N; Singh MP; Bhattacharya MK; Ghosh R; Kumar R; Sur D; Chadha SM; Saluja T Vaccine; 2014 Aug; 32 Suppl 1():A117-23. PubMed ID: 25091664 [TBL] [Abstract][Full Text] [Related]
79. A short report on clinical evaluation of RIX4414: highlights of world-wide development. De Vos B; Delem A; Hardt K; Bock HL; Meurice F; Innis B Vaccine; 2006 May; 24(18):3777-8. PubMed ID: 16584814 [No Abstract] [Full Text] [Related]
80. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Groome MJ; Moon SS; Velasquez D; Jones S; Koen A; van Niekerk N; Jiang B; Parashar UD; Madhi SA Bull World Health Organ; 2014 Apr; 92(4):238-45. PubMed ID: 24700991 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]